Adjustable Lymphedema Compression Wrap — the story so far

How to read this. This is a synthesis, not a new source of truth: every claim it cites carries the tag the candidate file gives it right now, copied not paraphrased, and every line quoted from a deck is quoted verbatim. See docs/narrative-spec.md.

What this was built against. The candidate file as of updated: 2026-09-29, which has 73 claims: 11 verified, 2 refuted, 43 unconfirmed, 17 unverified. That is after the Verifier's 2026-09-29 pass, the same-day rebuild of the business case (claims 57 to 66 appended), the rebuild of all three decks (claims 67 to 72 appended), and a second rebuild of the feasibility deck that corrected its own claim references and appended claim 73unverified. The candidate lists no macro-trend seeds. Several sections of the candidate file itself were written before the 2026-09-29 pass and have not been re-run since; they are named below where they bear on the story, not corrected here.

The one-paragraph version

This is a below-knee, inelastic, hook-and-loop strap wrap for adults with lower-extremity lymphedema in the maintenance phase who cannot pull on a flat-knit garment; what sets it apart from existing wraps is a printed mechanical window on each strap that lines up at a fixed tension. The candidate was designed backwards from Medicare code A6583 (a HCPCS code for a supply), on the premise that the code's descriptor names a 30-50 mmHg (millimetres of mercury) band the product could be sized to, and that premise is now refuted claim 8refuted: the descriptor reads "Gradient compression wrap with adjustable straps, below knee, each", with no pressure band claim 44verified. What the file does verify is the money around the code: a Part B benefit that names adjustable-strap wraps claim 42verified, a July 2026 non-rural allowable of $160.13 per wrap claim 11verified, and 80,433 wraps billed to 24,631 fee-for-service beneficiaries in 2024 claim 15verified. Nothing verified touches this device or its users: whether FDA (US Food and Drug Administration) reads an inelastic, lay-applied wrap into the exempt stocking regulation claim 6unconfirmed, whether the indicated population can strap it to tension unaided claim 23unconfirmed, and whether a new manufacturer can be coded to A6583 at all claim 32unconfirmed are all still open.

The story so far

The problem. Lymphedema maintenance therapy means compression applied every day by the patient, and the conventional product is a flat-knit garment pulled on over the foot. The candidate's premise is that a meaningful group of maintenance-phase patients fail or abandon that garment because they cannot get it on. That premise is on record only as an assumption claim 26unconfirmed. The published leads the file carries on donning difficulty come from other populations: an upper-limb cohort in Turkey claim 49unconfirmed and compression-hosiery wearers in the Netherlands claim 50unconfirmed, and the Verifier flagged both because their jurisdiction: US field does not match the study. The domain dossier searched for a measured share of the US lower-extremity lymphedema population unable to self-don a flat-knit garment, found none, and calls this the most load-bearing epidemiological gap for this candidate [dossier: lower-extremity-lymphedema-compression-therapy].

The mechanism. As the candidate's own mechanism: frontmatter describes it, the product is a set of overlapping inelastic bands held by hook-and-loop straps, each strap carrying a printed elongation window that lines up at a fixed strap tension, so the wearer can reproduce a target compression without a fitter, a dynamometer or electronics. None of the engineering behind that description has been tested:

• whether inelastic straps hold their tension through a wear period claim 37unconfirmed;
• whether one indicator setting gives a pressure inside a labelled band across the whole circumference range claim 71unverified;
• whether the windows calibrate the same across the circumference range and production lots claim 39unconfirmed;
• whether performance and calibration survive laundering and service life claim 40unconfirmed.

The one bench lead in the file limits the design space: in six marketed wraps tested on healthy subjects, inelastic wraps did not exceed roughly 30 mmHg at rest, while higher-stretch wraps went above 60 mmHg claim 48unconfirmed.

The regulatory design. The candidate chose its indication so that it would land on 21 CFR (Title 21 of the Code of Federal Regulations) 880.5780(b). That paragraph is Class I, exempt from premarket notification, and exempt from part 820 except for records and complaint files claim 2verified, and product code FQL maps to it claim 4verified. One line of venous "blood pooling" copy would move the product to paragraph (a), which is Class II (FDA device class II) with code DWL and carries no part 820 exemption claim 3verified, claim 5verified. The primary text that verifies all this also raises the open question. Both paragraphs identify a device "constructed of elastic material", and this device is inelastic by design; and § 880.9 requires a premarket notification where a device is intended for lay use and the earlier use was by health care professionals only, which is the fact pattern of self-application without a fitter claim 6unconfirmed. The file records these as FDA judgments no connector answers, and names a 513(g) request or regulatory counsel as the routes that would.

Why now. The candidate's timing rests on the Medicare Part B (Medicare Part B) lymphedema compression benefit for items furnished on or after 2024-01-01. The substance of that benefit is verified from regulation text: it names "gradient compression wraps with adjustable straps" claim 42verified, and it pays 80 percent of the lesser of the actual charge or a payment amount set under its own Medicaid/TRICARE/internet-retail method claim 43verified. The claim about where the benefit came from stays unconfirmed only because it names the "Lymphedema Treatment Act", a popular title the rule text read does not use claim 10unconfirmed. The candidate lists no seeds, so there is no macro-trend context to name.

What changed on 2026-09-29. The CMS (Centers for Medicare & Medicaid Services) HCPCS (Healthcare Common Procedure Coding System), DMEPOS (durable medical equipment, prosthetics, orthotics and supplies) fee-schedule, coverage and utilisation files arrived in data/, and the Verifier re-ran the reimbursement lines. Four claims moved to verified:

• the adjacent below-knee stocking codes A6552 and A6554, which carry explicit mmHg ranges claim 9verified;
• the payment rule, now with its $160.13 operand claim 11verified;
• the 2024 A6583 volume claim 15verified;
• the A6583 descriptor, which has no pressure band claim 44verified.

Two claims moved to refuted, both on the same lookup:

• the "30-50 mmHg" A6583 descriptor claim 8refuted;
• the bench condition that put the product's pressure target at "the 30-50 mmHg band named in the A6583 descriptor" claim 36refuted.

The Verifier states plainly that what is refuted in claim 36refuted is its reference to the descriptor; its performance half, whether a patient-applied wrap produces a gradient at all, was not refuted. The feasibility deck has restated that condition against a band the design team would choose claim 70unverified. The business case and the three decks were then rebuilt the same day and, between them, appended claims 57 to 73, all unverified.

What has and has not been checked. All eleven verified claims are about regulation text, code descriptors, the payment rule and billed volume. None covers the device's performance, what users can do, whether the channel would take the product, freedom to operate, or the number of competitors:

• FTO (freedom to operate) is an unexamined field, not a clear one claim 19unconfirmed.
• A patent sweep of the four named incumbents turned up a Canadian Essity application titled "Compression garment with indicator", recorded as a lead, not a finding claim 41unconfirmed. The same sweep found indicator art from unrelated assignees in the class, and that none of them holds an in-force US claim on the indicator is now on record, unchecked claim 73unverified.
• The competitor count is unmeasured rather than four claim 33unconfirmed, because a 510(k) (premarket notification) query says nothing about a generic type that is exempt from 510(k) claim 7unconfirmed.

Parts of the candidate file that predate the 2026-09-29 pass. The Verified Composite (re-scored 2026-08-29), the Gate Check (2026-08-25) and the Wrap section were all written before today's tag moves, and none has been re-run:

• The Gate Check says that "no claim in this file is refuted". Two claims now are.
• The Wrap section still cites claims 8, 11 and 12 as unconfirmed, quotes load-bearing conditions from earlier deck builds, and says data/ holds only README.md.
• The Stage 2 Scores table still gives the A6583 descriptor as carrying 30-50 mmHg.

This narrative reads the claim lines as they stand now and carries no score or gate result forward. Re-running those sections is work for /rescore, /gate-check and /wrap, not for a narrative.

What's solid

• 21 CFR 880.5780 exists and is titled "Medical support stocking" claim 1verified
• § 880.5780(b), the "general medical purposes" stocking, is Class I and exempt from premarket notification, subject to § 880.9, and also exempt from part 820 except records and complaint files claim 2verified
• § 880.5780(a), the stocking to prevent pooling of blood, is Class II (special controls); it is also premarket-exempt but does not carry the part 820 exemption claim 3verified
• Product code FQL is "Stocking, Medical Support (For General Medical Purposes)", Class I, under 880.5780 claim 4verified
• Product code DWL is "Stocking, Medical Support (To Prevent Pooling Of Blood In Legs)", Class II, under 880.5780 claim 5verified
• Below-knee stocking codes A6552 (30-40 mmHg) and A6554 (40 mmHg or greater) exist in the 2024 code set claim 9verified
• Medicare pays 80% of the lesser of the actual charge or the fee-schedule amount, with the Part B deductible applying; the July 2026 non-rural allowable for A6583 is $160.13 per wrap, which is Medicare's allowed amount before the 20% coinsurance, not its payment claim 11verified
• In data year 2024, national supplier-billed A6583 purchases came to 80,433 services (wraps) across 24,631 Medicare fee-for-service beneficiaries; the file calls this a floor on US volume from the code's first payable year, not a market size claim 15verified
• 42 CFR 410.36(a)(4) lists "gradient compression wraps with adjustable straps" in the Part B lymphedema compression treatment items benefit claim 42verified
• 42 CFR 414.1650(a) sets the payment basis for these items, A6583 included, at 80 percent of the lesser of the actual charge or its own computed payment amount, for items furnished on or after 2024-01-01 claim 43verified
• The A6583 descriptor reads "Gradient compression wrap with adjustable straps, below knee, each", with no mmHg qualifier, unlike A6552 and A6554 claim 44verified

None of these is about the device or its users. Between them they establish where the generic type sits in regulation, and the price and 2024 volume of a code the device would bill under. Whether this device belongs to that generic type, and whether its maker can reach that code, are in the next section.

What's still open

Refuted. These come first because they bear on the premise.

• A6583 is not defined by a "30-50 mmHg" band. The code exists, but its descriptor names no pressure range, and with that goes the "sized to the descriptor" premise that the candidate's title, positioning and Stage 2 Reimbursement row all lean on claim 8refuted
• The bench condition that put the product's pressure target at the descriptor's 30-50 mmHg band is refuted on the same ground; whether a patient-applied wrap produces a gradient at all is untested, not refuted claim 36refuted. It has been restated against a band chosen in the design claim 70unverified

Regulatory membership: whether this device is inside the exempt generic type

• Whether FDA reads an inelastic, strapped, lay-applied wrap into § 880.5780, given the "constructed of elastic material" identification and the § 880.9 lay-use and different-technology triggers claim 6unconfirmed
• Whether the self-application indication can be carried by human-factors validation alone, with no premarket notification and no clinical study claim 38unconfirmed
• Whether labelling the indicator as a strap self-application aid, with no mmHg measurement claim, keeps the device within § 880.5780(b) claim 72unverified
• If the exemption does not hold, whether a 510(k) or De Novo (De Novo classification request) route exists and can be funded and timed; no predicate has been identified, and no prior De Novo grant matches "compression" claim 56unconfirmed
• Whether an arterial-insufficiency contraindication and an ankle-brachial-index screening statement are required labelling content claim 21unconfirmed

Reimbursement: whether this product, from this manufacturer, gets paid

• Where the benefit came from, recorded under the popular title "Lymphedema Treatment Act" claim 10unconfirmed
• Whether coverage reaches any lymphedema diagnosis; the regulatory definition carries no subtype restriction, but the contractor policy article is unread claim 12unconfirmed
• RT/LT laterality modifiers claim 13unconfirmed; whether PDAC (Pricing, Data Analysis and Coding contractor) coding verification is required, and what quantity and replacement limits apply claim 14unconfirmed; the specific limit of three daytime wraps per body area per 6 months claim 45unconfirmed
• Whether a new manufacturer can get PDAC coding verification under A6583 without a clinical study and without already being in the fitter channel claim 32unconfirmed; whether the PDAC product list for A6583 already names a manufacturer beyond the four incumbents claim 61unverified
• Whether a manufacturer enrolled as a DMEPOS supplier can bill a wrap shipped home with no in-person fitting claim 65unverified; whether fewer than 100 suppliers dispensed more than half of 2024 A6583 volume claim 60unverified
• Whether A6583 carries PFS (physician fee schedule) status X, so that it is paid only as a DMEPOS item claim 59unverified
• Whether Medicare Advantage (Medicare Advantage), Medicaid and commercial payers pay on comparable terms claim 35unconfirmed; whether fee-for-service is less than half of US wrap volume claim 64unverified
• Whether the roughly $32 coinsurance per wrap drives abandonment claim 53unconfirmed; whether a cash-pay channel above the coinsurance would hold up claim 55unconfirmed
• Dossier context, not evidence: a PDAC coding-and-billing article (revised 2026-04-08) says medical records must document the lymphedema diagnosis by an MD/DO/NP/PA/CNS and that SC, GA, GY or GZ modifiers are required; it did not state a PDAC coding-verification requirement, which the dossier reads as "not found in this document", not "no such requirement" [dossier: lower-extremity-lymphedema-compression-therapy]
• Dossier context, not evidence: 42 CFR 414.1670 sets out a separate CMS process for deciding whether a new item qualifies as a lymphedema compression treatment item, and the dossier found nothing suggesting this indicator would trigger it [dossier: lower-extremity-lymphedema-compression-therapy]

Economics

• Net selling price per wrap under the $160.13 ceiling claim 16unconfirmed; the Generator's 10-20% obtainable share claim 17unconfirmed; the 3-5 million prevalence figure, which the file forbids multiplying by anything claim 18unconfirmed
• Whether the manufacturer keeps a positive gross margin after the channel margin claim 31unconfirmed; whether incumbents' wholesale prices sit below the allowable claim 62unverified; whether this wrap can be landed below that wholesale price claim 63unverified
• The comparison of 2024 stocking-code volumes against A6583 claim 57unverified; the stocking-code allowables claim 58unverified; whether 2025 A6583 volume exceeds 2024 claim 69unverified
• Capital and time to first claim, deliberately stated with no figure claim 22unconfirmed; turnaround from registration to first billable claim claim 51unconfirmed; whether the launch can be financed claim 52unconfirmed

Users, clinicians and the channel

• Whether patients who cannot self-don a flat-knit garment can self-apply a multi-strap wrap and read its indicators claim 23unconfirmed; whether they re-apply to target tension over months claim 27unconfirmed; whether the indicator makes their achieved tension more consistent than a strap without one claim 68unverified
• Whether a commercially available donning aid already meets the need claim 67unverified
• Whether clinicians would accept a self-applied wrap claim 25unconfirmed; whether prescribers would document arterial status first claim 28unconfirmed; whether patients would notice an early change claim 29unconfirmed; whether a caregiver would be available where the patient cannot strap it claim 30unconfirmed
• Whether fitters and DMEPOS suppliers would stock a fifth brand claim 24unconfirmed
• Literature leads, which by rule cannot be tagged above unconfirmed:
  • adjustable wraps went on 8.4 minutes faster than multilayer bandaging, but in the intensive phase claim 46unconfirmed;
  • 95.3% of 86 chronic-leg-oedema patients could don another maker's inelastic system independently or with a little help claim 47unconfirmed;
  • donning-related discontinuation in upper-limb and hosiery cohorts outside the US claim 49unconfirmed, claim 50unconfirmed
• Dossier context, not evidence: no located publication tests whether patients apply adjustable wraps at sub-therapeutic tension at home, or whether a printed elongation window changes that rate; the dossier calls this the single biggest evidence gap for the product's differentiator [dossier: lower-extremity-lymphedema-compression-therapy]
• Dossier context, not evidence: care pathway and user incentives are essentially unsearched; the ISL 2023 consensus document was located but its maintenance-phase garment-selection text could not be retrieved; and an upper-limb RCT (randomised controlled trial) of 71 women in Brazil found no adherence difference between adjustable wraps and compressive mesh [dossier: lower-extremity-lymphedema-compression-therapy]

IP (intellectual property), moat and competitors

• FTO is unexamined claim 19unconfirmed; the Essity indicator application is a lead with no US member found claim 41unconfirmed; whether any assignee outside the four incumbents holds an in-force US claim on the indicator claim 73unverified; whether the indicator could be patented claim 66unverified
• The moat, which the file itself calls weak claim 20unconfirmed; whether incumbents would not copy the indicator claim 34unconfirmed; whether an incumbent would license it instead claim 54unconfirmed
• Whether the field is limited to the four named firms claim 33unconfirmed; a 510(k) null is uninformative for an exempt type, and one "compression wrap" query returned an unrelated powered device claim 7unconfirmed
• Dossier context, not evidence: the only incumbent recall found was a 2022 JOBST Compri2 carton-labelling error, now terminated, and firm-level recall queries for medi, Sigvaris and Solaris returned nothing; the dossier also notes a trend towards sensor-equipped compression garments, which one review flags as facing unresolved regulatory challenges [dossier: lower-extremity-lymphedema-compression-therapy]

On the dossier itself. The dossier was built on 2026-08-27, before the CMS files arrived. Its reimbursement section treats the A6583 mmHg question as open and the HCPCS master file as unloaded; both have since been settled on the claim side, by claims 8 and 44. The dossier's own finding at the time, that the PDAC article showed no mmHg qualifier on A6583, turned out consistent with what the Verifier later read. The dossier has not been refreshed and is left as it stands.

Where the three lenses agree — and where they don't

All three decks exist. Each was built on 2026-09-29 against source_updated: 2026-09-29, and check_decks.py reports all three as current, not STALE, at the time this narrative was built. The feasibility deck is the second build of that date: the earlier one cited the single-tension condition and the strap-aid labelling condition under each other's claim numbers, and the current build says so on its own opening page and cites them by position as the file numbers them. Checked against the claim text at each position, the references this narrative relies on in all three decks now point where they say. The decks agree on one thing: none of the verified claims supports a condition on any deck. Each treats the regulation, code, price and volume lines as context around its conditions, and each deck's "where this deck outruns the file" slide lists all of its conditions. Where they differ is which gap comes first, and the three answers depend on each other more than any one deck says.

Desirability. This deck sits in the patient's chair, with the clinician, the fitter and the caregiver behind the patient. Every condition on it rests on unconfirmed or unverified. It uses the verified 2024 volume claim 15verified against the product rather than for it: an adjustable-strap wrap already reaches Medicare users without this product's indicator. So the deck puts two questions together as its crux: can the indicated population strap the wrap unaided claim 23unconfirmed, and does the indicator, not the wrap, make that repeatable claim 68unverified? Its fallback, a caregiver doing the strapping claim 30unconfirmed, would change who the user is, which touches the feasibility deck's lay-use question because both rest on the same self-application fact.

"whether a patient who cannot self-don a flat-knit garment can strap this wrap to its indicated tension, unaided, and does so more consistently because of the indicator" — the load-bearing condition of the desirability deck (built 2026-09-29).

Viability. This deck is written for the investor and operator, and it holds the most verified backing of the three: the benefit, the payment rule, the allowable and the volume. It reads the refuted descriptor premise claim 8refuted as cutting both ways: a code with no pressure band is open to any adjustable-strap wrap, which helps billing and hurts differentiation. So it stops asking what Medicare pays and asks whether a new manufacturer can reach any of that money, naming the PDAC's product list for A6583 claim 61unverified as the cheapest window onto it. Its moat slide lands on the same indicator the desirability deck asks about, and records the moat as weak in the file's own words claim 20unconfirmed.

"whether a new manufacturer's adjustable-strap wrap can be coded to A6583 by the PDAC without a clinical study and without already being in the fitter channel" — the load-bearing condition of the viability deck (built 2026-09-29).

Feasibility. This deck is written for engineering, and it notes that every verified claim on it concerns the regulation and the code, none the device. It restates the refuted bench condition as a band the design team would have to choose claim 70unverified, and flags the roughly 30 mmHg ceiling for inelastic wraps from the one bench lead claim 48unconfirmed as a limit on that choice. Its hardest unknown is whether one strap tension and one indicator setting serve every circumference in the labelled range claim 71unverified; its regulatory slide carries the separate question of whether strap-aid labelling keeps the device off a measurement regulation claim 72unverified. Its FTO slide now reaches past the four incumbents to unrelated assignees' indicator art claim 73unverified. It picks the regulatory question over all the bench questions, because the answer sets which engineering programme exists at all.

"whether FDA reads an inelastic adjustable-strap wrap, indicated for lay self-application without a fitter, into 21 CFR 880.5780(b) — or whether the elastic-material identification or the § 880.9 lay-use trigger puts it on a premarket route" — the load-bearing condition of the feasibility deck (built 2026-09-29).

How the three connect. Viability and feasibility each ask how the product reaches the market: through which coding door, and on which FDA route. Desirability asks whether there is a distinct product to carry through either door. The refutation of claim 8refuted moved weight towards that last question. With the "sized to the code" premise gone, the printed indicator is the only thing the file names that separates this wrap from the adjustable-strap wraps Medicare already pays for, and that same indicator has to stay a strap aid, not a measurement, to keep the regulatory design intact claim 72unverified, and has to be free of anyone else's claims to be worth anything claim 19unconfirmed.

The load-bearing question

With A6583 open to any adjustable-strap below-knee wrap, does the printed strap tension indicator let patients who cannot self-don a flat-knit garment reach design tension, unaided and at every donning, more consistently than the same wrap without it, while remaining only a strap self-application aid?

This question comes from the three decks' load-bearing conditions without being any one of them. The candidate was built on a code-fit premise that is now refuted claim 8refuted, and the verified 2024 volume claim 15verified shows that adjustable-strap wraps already reach Medicare patients without an indicator. The viability deck's coding question claim 32unconfirmed and the feasibility deck's classification question claim 6unconfirmed each decide how the product would reach the market; this question decides whether there is anything distinct to take there. It holds three conditions together: the indication's own premise claim 23unconfirmed, the indicator's contribution claim 68unverified, and the labelling limit that keeps the indicator off a measurement regulation claim 72unverified. The desirability deck names supervised then unsupervised donning sessions, with the indicators masked and unmasked, as the cheap way to observe it, and only a human with patient access can run them.

Naming it is not a recommendation, a gate, or a kill. It is the answer to "if a human could only read one more thing about this candidate, what question should it answer."